ArticleBMC pulmonary medicine2025
The poly (ADP-ribose) polymerase inhibitor olaparib attenuates established pulmonary fibrosis in a large animal model.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPoly (ADP‒ribose) polymerase (PARP) is a constitutive enzyme involved in regulating various biological processes in health and disease. In the present study, we investigated the role of PARP1 in pulmonary fibrosis and assessed the efficacy of a clinically approved PARP inhibitor, olaparib, for the treatment of pulmonary fibrosis in a large animal bleomycin model.
methodsSheep (n = 12) received two fortnightly instillations of bleomycin (3 U) and saline into separate lung lobes of the same animal. Two weeks after the second bleomycin/saline exposure, sheep were randomly assigned to two groups and treated twice/week orally with either olaparib (10 mg/kg; treated group) or vehicle solution (control group) for four weeks. Olaparib concentrations in plasma were analysed using ultra-high-performance liquid chromatography. The degree of inflammation and fibrosis was assessed using a semiquantitative histopathology scoring method. Masson’s trichrome staining and hydroxyproline assays were used to evaluate collagen deposition in the lungs. We also determined whether olaparib treatment was targeting the migration of sheep lung fibroblasts in vitro using a 2D wound scratch assay.
resultsOlaparib was rapidly taken up into plasma following oral delivery, returning to baseline levels within 24 h. Therapeutically, olaparib treatment significantly reduced bleomycin-induced PARP1 overexpression and attenuated lung injury and fibrosis. Inflammation and fibrosis scores were significantly lower in bleomycin-injured lobes of sheep treated with olaparib compared to those treated with vehicle only. Additionally, a significant reduction in collagen deposition in the lungs of olaparib-treated sheep compared to vehicle-treated sheep was demonstrated by histopathology and hydroxyproline analyses. In vitro, olaparib significantly inhibited the migration of primary sheep lung fibroblasts.
conclusionsOlaparib treatment reduced bleomycin-induced PARP1 overexpression and significantly attenuated established pulmonary fibrosis. Our data suggest that the activation of PARP1 plays a key role in the pathology of pulmonary fibrosis, and provides strong support for the potential repurposing of olaparib and similar PARP inhibitors for the treatment of pulmonary fibrosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.